- Home
- LSF vs OTLK Comparison
LSF vs OTLK Comparison
Compare LSF & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LSF | OTLK |
|---|---|---|
| Founded | 2015 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.3M | 29.2M |
| IPO Year | 2020 | 2016 |
Fundamental Metrics
Financial Performance| Metric | LSF | OTLK |
|---|---|---|
| Price | $2.39 | $0.25 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $6.00 | $2.50 |
| AVG Volume (30 Days) | 41.4K | ★ 3.4M |
| Earning Date | 05-06-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 75.28 | 55.91 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $49,889,286.00 | $8,146,123.00 |
| Revenue This Year | $40.85 | $1,430.98 |
| Revenue Next Year | $28.72 | $173.23 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 15.23 | N/A |
| 52 Week Low | $1.96 | $0.16 |
| 52 Week High | $7.94 | $3.39 |
Technical Indicators
Market Signals| Indicator | LSF | OTLK |
|---|---|---|
| Relative Strength Index (RSI) | 51.01 | 37.81 |
| Support Level | $2.41 | $0.16 |
| Resistance Level | $2.76 | $0.46 |
| Average True Range (ATR) | 0.20 | 0.04 |
| MACD | 0.04 | 0.00 |
| Stochastic Oscillator | 76.17 | 38.44 |
Price Performance
Historical ComparisonAbout LSF Laird Superfood Inc.
Laird Superfood Inc is engaged in the business of manufacturing and marketing differentiated plant-based and functional foods. The product portfolio includes Coffee creamers, Hydration products and beverage-enhancing supplements, Harvest snacks and various other food items, and Coffee, tea, and hot chocolate products.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.